Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

ImmunoPET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors.

Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, Al-Azzam W, Chen L, Verheul H, Hoekstra OS, Vugts DJ, Freedman I, Huisman M, Matheny C, van Dongen G, Zhang S.

J Nucl Med. 2019 Feb 7. pii: jnumed.118.214726. doi: 10.2967/jnumed.118.214726. [Epub ahead of print]

PMID:
30733323
2.

Identification of new molecular targets for PET imaging of the microglial anti-inflammatory activation state.

Villa A, Klein B, Janssen B, Pedragosa J, Pepe G, Zinnhardt B, Vugts DJ, Gelosa P, Sironi L, Beaino W, Damont A, Dollé F, Jego B, Winkeler A, Ory D, Solin O, Vercouillie J, Funke U, Laner-Plamberger S, Blomster LV, Christophersen P, Vegeto E, Aigner L, Jacobs A, Planas AM, Maggi A, Windhorst AD.

Theranostics. 2018 Oct 27;8(19):5400-5418. doi: 10.7150/thno.25572. eCollection 2018.

3.

F8-IL10: a new potential anti-rheumatic drug evaluated by a PET-guided translational approach.

Bruijnen STG, Chandrupatla DMSH, Giovanonni L, Neri D, Vugts DJ, Huisman MC, Hoekstra OS, Musters RJP, Lammertsma AA, van Dongen GA, Jansen G, Molthoff CFM, van der Laken CJ.

Mol Pharm. 2018 Dec 14. doi: 10.1021/acs.molpharmaceut.8b00982. [Epub ahead of print]

PMID:
30550295
4.

Fully automated zirconium-89 labeling and purification of antibodies.

Poot AJ, Adamzek KWA, Windhorst AD, Vosjan M, Kropf S, Wester HJ, van Dongen GAMS, Vugts DJ.

J Nucl Med. 2018 Dec 7. pii: jnumed.118.217158. doi: 10.2967/jnumed.118.217158. [Epub ahead of print]

PMID:
30530830
5.

A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer.

Sibinga Mulder BG, Handgraaf HJ, Vugts DJ, Sewing C, Windhorst AD, Stammes M, de Geus-Oei LF, Bordo MW, Mieog JSD, van de Velde CJ, Frangioni JV, Vahrmeijer AL.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):282-291. eCollection 2018.

6.

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.

van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM, Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW.

Oncotarget. 2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018 May 15.

7.

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images.

Jauw YWS, Heijtel DF, Zijlstra JM, Hoekstra OS, de Vet HCW, Vugts DJ, Verheul HM, Boellaard R, Zweegman S, van Dongen GAMS, der Houven van Oordt CWM, Lammertsma AA, Huisman MC.

Mol Imaging Biol. 2018 Dec;20(6):1025-1034. doi: 10.1007/s11307-018-1200-4.

8.

Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation.

Janssen B, Vugts DJ, Wilkinson SM, Ory D, Chalon S, Hoozemans JJM, Schuit RC, Beaino W, Kooijman EJM, van den Hoek J, Chishty M, Doméné A, Van der Perren A, Villa A, Maggi A, Molenaar GT, Funke U, Shevchenko RV, Baekelandt V, Bormans G, Lammertsma AA, Kassiou M, Windhorst AD.

Sci Rep. 2018 Apr 26;8(1):6580. doi: 10.1038/s41598-018-24814-0.

9.

PET Imaging of Microglial Activation-Beyond Targeting TSPO.

Janssen B, Vugts DJ, Windhorst AD, Mach RH.

Molecules. 2018 Mar 8;23(3). pii: E607. doi: 10.3390/molecules23030607. Review.

10.

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.

Jauw YWS, Huisman MC, Nayak TK, Vugts DJ, Christen R, Naegelen VM, Ruettinger D, Heil F, Lammertsma AA, Verheul HMW, Hoekstra OS, van Dongen GAMS, Menke-van der Houven van Oordt CW.

EJNMMI Res. 2018 Jan 22;8(1):6. doi: 10.1186/s13550-018-0358-8.

11.

Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X7 Receptor Antagonist.

Wilkinson SM, Barron ML, O'Brien-Brown J, Janssen B, Stokes L, Werry EL, Chishty M, Skarratt KK, Ong JA, Hibbs DE, Vugts DJ, Fuller S, Windhorst AD, Kassiou M.

ACS Chem Neurosci. 2017 Nov 15;8(11):2374-2380. doi: 10.1021/acschemneuro.7b00272. Epub 2017 Aug 25.

PMID:
28841278
12.

Fluorine-18 labelled building blocks for PET tracer synthesis.

van der Born D, Pees A, Poot AJ, Orru RVA, Windhorst AD, Vugts DJ.

Chem Soc Rev. 2017 Jul 31;46(15):4709-4773. doi: 10.1039/c6cs00492j. Review.

PMID:
28608906
13.

Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.

Alsaid H, Skedzielewski T, Rambo MV, Hunsinger K, Hoang B, Fieles W, Long ER, Tunstead J, Vugts DJ, Cleveland M, Clarke N, Matheny C, Jucker BM.

PLoS One. 2017 Apr 27;12(4):e0176075. doi: 10.1371/journal.pone.0176075. eCollection 2017.

14.

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

15.

ESPMIS: Helping Young Scientists Navigate the Molecular Imaging Landscape.

Zeglis BM, Vugts DJ.

Mol Imaging Biol. 2017 Jun;19(3):325-327. doi: 10.1007/s11307-017-1053-2.

PMID:
28194633
16.

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Jauw YW, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, van Dongen GA, Huisman MC.

PLoS One. 2017 Jan 6;12(1):e0169828. doi: 10.1371/journal.pone.0169828. eCollection 2017.

17.

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.

van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, Dubois L, Dingemans AC, Lalisang RI, Kempers P, Brans B, Winnepenninckx V, Speel EJ, Thunnissen E, Smits KM, Boellaard R, Vugts DJ, De Ruysscher D, Lambin P.

Radiother Oncol. 2017 Feb;122(2):267-273. doi: 10.1016/j.radonc.2016.11.020. Epub 2016 Dec 21.

PMID:
28012793
18.

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.

Even AJ, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJ, Heukelom J, Tesselaar ME, Vogel WV, Hoeben A, Zegers CM, Vugts DJ, van Dongen GA, Bartelink H, Mottaghy FM, Hoebers F, Lambin P.

Oncotarget. 2017 Jan 17;8(3):3870-3880. doi: 10.18632/oncotarget.13910.

19.

Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma.

Jansen MH, Veldhuijzen van Zanten SEM, van Vuurden DG, Huisman MC, Vugts DJ, Hoekstra OS, van Dongen GA, Kaspers GL.

J Nucl Med. 2017 May;58(5):711-716. doi: 10.2967/jnumed.116.180216. Epub 2016 Oct 20.

20.

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET.

Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, Mari C, Visser GWM, Valverde IE, Gasser G, Mindt TL, van Dongen GAMS.

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):286-295. doi: 10.1007/s00259-016-3499-x. Epub 2016 Aug 30.

Supplemental Content

Loading ...
Support Center